Archiv der Kategorie ‘Amylin Pharma‘

Amylin Pharma (AMLN) Downgrade from Outperform to Neutral – Analyst rating from Robert W. Baird

Thursday, den 31. May 2012

Amylin Pharma ( AMLN ) Upgrade from Sell to Neutral – Analyst rating from MKM Partners

Thursday, den 29. March 2012

Amylin Pharma (AMLN) Upgrade from Sell to Neutral – Analyst rating from MKM Partners

Thursday, den 29. March 2012

Amylin Pharma ( AMLN ) Initial Recommendation Sell – Analyst rating from Canaccord Genuity

Monday, den 26. March 2012

Amylin Pharma (AMLN) Initial Recommendation – Sell – Analyst rating from Canaccord Genuity

Monday, den 26. March 2012

Amylin Pharma ( AMLN ) Downgrade from Neutral to Sell($8.5) – Analyst rating from MKM Partners

Wednesday, den 11. January 2012

Amylin Pharma (AMLN) Downgrade from Neutral to Sell – Analyst rating from MKM Partners

Wednesday, den 11. January 2012

Amylin Pharma ( AMLN ) Initial Recommendation Mkt Underperform – Analyst rating from Rodman & Renshaw

Thursday, den 5. January 2012

Amylin Pharma (AMLN) Initial Recommendation – Mkt Underperform – Analyst rating from Rodman & Renshaw

Thursday, den 5. January 2012

Amylin Pharma ( AMLN ) Initial Recommendation Accumulate – Analyst rating from Global Hunter Securities

Wednesday, den 7. December 2011

Amylin Pharma (AMLN) Initial Recommendation – Accumulate – Analyst rating from Global Hunter Securities

Wednesday, den 7. December 2011

Amylin Pharma (AMLN) Upgrade from Neutral to Outperform – Analyst rating from Robert W. Baird

Monday, den 14. November 2011

Amylin Pharma ( AMLN ) Upgrade from Neutral to Outperform($15) – Analyst rating from Robert W. Baird

Monday, den 14. November 2011

Amylin Pharma (AMLN) Upgrade from Neutral to Buy – Analyst rating from Summer Street Research

Thursday, den 20. October 2011

Amylin Pharma ( AMLN ) Upgrade from Neutral to Buy($17) – Analyst rating from Summer Street Research

Thursday, den 20. October 2011

Amylin Pharma (AMLN) Downgrade from Buy to Average – Analyst rating from Caris & Company

Wednesday, den 20. October 2010

Amylin Pharma ( AMLN ) Downgrade from Buy to Average($12) – Analyst rating from Caris & Company

Wednesday, den 20. October 2010